Inhibition of retinoic acid metabolism for reversal of cognitive deficits in AD

Award Information
Agency:
Department of Health and Human Services
Branch
n/a
Amount:
$225,000.00
Award Year:
2013
Program:
STTR
Phase:
Phase I
Contract:
1R41AG046987-01
Award Id:
n/a
Agency Tracking Number:
R41AG046987
Solicitation Year:
2013
Solicitation Topic Code:
NIA
Solicitation Number:
PA13-089
Small Business Information
6610 JUSTIN CT, MISSOULA, MT, 59803-2969
Hubzone Owned:
N
Minority Owned:
N
Woman Owned:
Y
Duns:
78771732
Principal Investigator:
FANNYASTRUC-DIAZ
(406) 243-4354
fanny_diaz2008@yahoo.com
Business Contact:
FANNYDIAX
(832) 677-3756
fanny_diaz2008@yahoo.com
Research Institute:
UNIVERSITY OF WASHINGTON

UNIVERSITY OF WASHINGTON
Office of Sponsored Programs 4333 Brooklyn Ave NE Box 359472
SEATTLE, WA, 98195-9472
() -

Abstract
DESCRIPTION (provided by applicant): Alzheimer's disease (AD) is a progressive and ultimately fatal neurodegenerative disease that affects more than five million people in the USA. Currently there is no cure for AD. Available medicines are aimed only at temporarily reducing symptoms and slowing down the progression of the disease. While many new compounds have been developed to treat AD, they have not been successful in clinical studies and consequently there is a great need for development of new therapeutic strategies. Recent data show that retinoic acid (RA) plays an important role in maintaining neuronal plasticity, and learning and memory in human or in transgenic animal model of AD, and support our hypothesis that increasing RA in the brain will improve AD patient outcomes. However, RA has poor pharmacokinetics in humans and it induces its own clearance resulting in loss of activity during long-term use. In this STTR effort, Dermaxon will use inhibition of RA clearance, instead of treatment with RA itself as a novel therapeutic strategy to treat or prevent progression of cognitive impairments associated with AD. The clearance of RA is predominantly mediated by cytochrome P450 family 26 enzymes (CYP26) of which there are three isoforms: CYP26A1, CYP26B1and CYP26C1. While CYP26A1 appears to be the human liver RA hydroxylase, CYP26B1 is predicted to be responsible for RA metabolism in extrahepatic tissues and CYP26C1 appears to prefer 9cis-RA as a substrate. In preliminary studies, different chemotypes with a nanomolar IC50 at CYP26A1 and/or CYP26B1 have been identified. Such a novel class of compounds is expected to be highly specific for the different CYP26 isoforms, thereby avoiding side effects and non-target P450 inhibition associated with previouslydescribed CYP26 inhibitors. Dermaxon's goal is to develop the next generation of novel selective inhibitors of CYP26, to increase RA concentration in the brain, and to treat memory impairment associated with AD. Using our previously discovered lead structures, we will first generate a series of new compounds with improved CYP26 inhibition potency and selectivity. We will then evaluate their pharmacokinetic properties in mice as well as their efficacy in rescuing memory deficits in the AD mouse model PS1-APP. By the end of this Phase I STTR, Dermaxon will have identified a candidate compound that selectively targets CYP26B1 and also provide evidence that these compounds exhibit in vivo efficacy in rescuing the memory deficit in AD mouse model. In the Phase II of this STTR project we will initiate FDA discussions and complete pre-clinical studies required to file an Investigational New Drug Application (IND) to initiate clinical studies. PUBLIC HEALTH RELEVANCE PUBLIC HEALTH RELEVANCE: Demaxon hasoutlined a strategy for developing novel inhibitors of CYP26 enzymes that are responsible for the clearance of retinoic acid, as a therapeutic approach to improve learning and memory in Alzheimer's disease patients. In America alone, more than five million patients currently suffer from Alzheimer's disease or some form of dementia and this figure is expected to jump to 13.8M by 2050 with the associated cost of long- term care services reaching 1.2 trillion a year. The outcome of this STTR Phase I will validate CYP26 as druggable target for the treatment of neurodegenerative disease and generate data necessary to develop the most promising CYP26 inhibitor as a new approach to treating Alzheimer's disease.

* information listed above is at the time of submission.

Agency Micro-sites


SBA logo

Department of Agriculture logo

Department of Commerce logo

Department of Defense logo

Department of Education logo

Department of Energy logo

Department of Health and Human Services logo

Department of Homeland Security logo

Department of Transportation logo

Enviromental Protection Agency logo

National Aeronautics and Space Administration logo

National Science Foundation logo
US Flag An Official Website of the United States Government